Straws in the wind? Sandoz to shut API devt centre in India
Sandoz, the world’s second-largest generic drugs company and a unit of Swiss drug maker Novartis has decided to shut its active pharmaceutical ingredients or API development facility near Mumbai. A...
View ArticleBeyond Glivec : Balancing innovation and public health
I’d like to introduce a guest column by Dr Kristina Lybecker, Associate Professor of Economics at Colorado College in Colorado Springs. Kristina is an economist with a PhD from the University of...
View ArticleScoop : Sandoz shutters India formulations R&D
Sandoz, the generics arm of Swiss drug maker Novartis AG, has decided to shutter a second research and development (R&D) centre in India in under 12 months. This time it is the formulations or...
View ArticleIndia and drug #patents : The Ghost of #Glivec haunts #Sovaldi
Apothecurry welcomes back guest columnist Dr Kristina Lybecker. Her latest column is an elegantly simple “where the rubber hits the road” exposition of the recent rejection of patents on US biopharma...
View Article
More Pages to Explore .....